Clinical Trial Update: The HER Project: HRD in EGFR-mutated NSCLC

View source ↗

Summary

An update on an ongoing clinical trial investigating homologous recombination deficiency in EGFR-mutated non-small cell lung cancer using a PARP inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: IRCCS San Raffaele | Conditions: EGFR, Non Small Cell Lung Cancer | Status: ACTIVE_NOT_RECRUITING